前列腺癌人源性异种移植裸鼠模型 z-bo 2020-12-29 322

　　Objective: To establish a human-derived xenograft model of prostate cancer and evaluate the anti-tumor effects of different treatment options.

　　Methods: Fresh human prostate cancer surgical specimens were mixed with Matrigel and transplanted into nude mice supplemented with exogenous androgen subcutaneously. The tumor growth was continuously monitored, and its fidelity was evaluated and serially passaged. The tumor-bearing mice were divided into four Group: docetaxel group, castration group, docetaxel combined castration group and control group. The tumor volume and the weight change of mice were measured during the treatment period. After the treatment, the total prostate specific antigen (total prostate specific antigen) in the serum was detected. Specific antigen, tPSA) concentration and histopathological changes, to evaluate the therapeutic effect.

　　Results: The PDX model of prostate cancer was successfully established, including hormone-sensitive (D17225) and castration-resistant (C40019) tumors. Pathological analysis found that the transplanted tumor better maintained the main characteristics of the patient's primary tumor; histopathological and Serum tPSA test found that the docetaxel group and the docetaxel combined castration group showed good therapeutic effects in the D17225 model, and the latter has a more obvious tumor suppressing effect.

　　Conclusion: Successfully established a prostate cancer PDX model and stable passage, docetaxel alone or combined castration treatment has a significant therapeutic effect on hormone-sensitive (D17225) prostate cancer PDX model.